Chemotherapy-free anlotinib-based regimens in advanced non-small cell lung cancer: a real-world retrospective cohort study.

Although this survival advantage did not reach statistical significance in the current cohort (P>0.05)—likely a reflection of the limited sample size—the substantial extension in median survival represents a clinically meaningful signal that warrants further verification in larger studies.

also in 111,027 other papers

10 months), earlier anlotinib use still showed a trend toward improved survival.

also in 53,322 other papers